Day One Biopharmaceuticals, LLC expects top-line Phase II data for its lead candidate, DAY101, in June. The pan-RAF kinase inhibitor is under investigation in the FIREFLY-1 study for pediatric low-grade glioma (pLGG), the most frequent type of brain tumor in children.
The US biotech first got hold of the asset from Takeda Pharmaceutical Co. Ltd. in 2020 and Phase I...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?